Compared to the initial standard-dose BB therapy group, patients in the high-dose group were younger, exhibited lower cTnT levels, showed a reduced prevalence of CHD and AMI, and had an increased prevalence of cardiomyopathy and rheumatic heart disease. This evidence concerns the gene TNNT2 and coronary artery disorder.